Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lu AG09222 in Healthy Caucasian, Chinese, and Japanese Subjects
NCT05304910Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu ag09222 in migraine (3 arms), sponsored by Lundbeck. Primary endpoints: Area Under the Serum Concentration-Time Curve From Zero to Infinity, Maximum Observed Concentration and 4 more. Started Mar 2022; status: completed.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05304910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304910.